"Not So Different": AmerisourceBergen's Sean McGowan Takes a Closer Look at US Biosimilar Launches

On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.

On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.

Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.

On this episode of Not So Different, Vizient’s Carina Dolan, PharmD, MS, BCOP, expounds on some of the results from Vizient’s recent edition of its Pharmacy Market Outlook Report, including how inflation could influence biosimilar utilization.

We sat down with Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center, to discuss what practices have had to forgo during the coronavirus disease 2019 (COVID-19) crisis and how biosimilar access has been affected.

Kanika Monga, MD, of the American College of Rheumatology’s (ACR) Communication and Marketing Committee, and Angus Worthing, MD, an ACR director, discuss the ACR's recent survey on rheumatology.